Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trials.
Volkmann ER, Tashkin DP, Silver R, Bostwick CF, Assassi S, Frost DB, Leng M, Wilhalme H, Kim GH, Goldin J, Roth MD. Volkmann ER, et al. Among authors: roth md. Lancet Rheumatol. 2022 Oct;4(10):e668-e678. doi: 10.1016/s2665-9913(22)00193-x. Epub 2022 Sep 21. Lancet Rheumatol. 2022. PMID: 37745675 Free PMC article.
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM; Sclerodema Lung Study II Investigators. Tashkin DP, et al. Among authors: roth md. Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25. Lancet Respir Med. 2016. PMID: 27469583 Free PMC article. Clinical Trial.
Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM. Volkmann ER, et al. Among authors: roth md. Arthritis Rheumatol. 2017 Jul;69(7):1451-1460. doi: 10.1002/art.40114. Epub 2017 May 23. Arthritis Rheumatol. 2017. PMID: 28376288 Free PMC article.
Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
Volkmann ER, Tashkin DP, Kuwana M, Li N, Roth MD, Charles J, Hant FN, Bogatkevich GS, Akter T, Kim G, Goldin J, Khanna D, Clements PJ, Furst DE, Elashoff RM, Silver RM, Assassi S. Volkmann ER, et al. Among authors: roth md. Arthritis Rheumatol. 2019 Dec;71(12):2059-2067. doi: 10.1002/art.41020. Epub 2019 Nov 1. Arthritis Rheumatol. 2019. PMID: 31233287 Free PMC article.
Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease.
Kim GHJ, Tashkin DP, Lo P, Brown MS, Volkmann ER, Gjertson DW, Khanna D, Elashoff RM, Tseng CH, Roth MD, Goldin JG. Kim GHJ, et al. Among authors: roth md. Arthritis Rheumatol. 2020 Feb;72(2):316-325. doi: 10.1002/art.41085. Epub 2019 Dec 26. Arthritis Rheumatol. 2020. PMID: 31430058 Free PMC article.
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis.
Volkmann ER, Tashkin DP, Roth MD, Li N, Charles J, Mayes M, Kim G, Goldin J, Pourzand L, Clements PJ, Furst DE, Khanna D, Elashoff RM, Assassi S. Volkmann ER, et al. Among authors: roth md. Semin Arthritis Rheum. 2020 Oct;50(5):963-967. doi: 10.1016/j.semarthrit.2020.06.003. Epub 2020 Jun 16. Semin Arthritis Rheum. 2020. PMID: 32906032 Free PMC article. Clinical Trial.
Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease.
Assassi S, Li N, Volkmann ER, Mayes MD, Rünger D, Ying J, Roth MD, Hinchcliff M, Khanna D, Frech T, Clements PJ, Furst DE, Goldin J, Bernstein EJ, Castelino FV, Domsic RT, Gordon JK, Hant FN, Shah AA, Shanmugam VK, Steen VD, Elashoff RM, Tashkin DP. Assassi S, et al. Among authors: roth md. Arthritis Rheumatol. 2021 Jun;73(6):1005-1013. doi: 10.1002/art.41627. Epub 2021 Apr 20. Arthritis Rheumatol. 2021. PMID: 33350170 Free PMC article.
147 results